S-1: Dror Ortho-Design, Inc. Files S-1 for Public Offering to Fund AI-Based Orthodontic Platform Amidst Going Concern Warning

Dror Ortho-Design, Inc., a development-stage company with no current revenues, has filed an S-1 registration statement to offer common stock and warrants, seeking to raise capital for its proprietary AI-based ZSmile orthodontic platform while facing substantial doubt about its ability to continue as a going concern.

Summary

• Dror Ortho-Design, Inc. is a development-stage company focused on an AI-based orthodontic alignment platform called ZSmile, designed to correct smiles discreetly and less painfully using a single smart aligner with pulsating air during sleep.
• The company's first-generation product, the Aerodentis System, received FDA 510(k) clearance in April 2020, but the updated ZSmile Platform requires a new 510(k) clearance, which has not yet been filed.
• Dror Ortho-Design currently generates no revenues and has incurred significant net operating losses, including $5.8 million for the year ended December 31, 2024, and $576,123 for the three months ended March 31, 2025.
• As of March 31, 2025, the company had a cash balance of $349,851 and an accumulated deficit of $20,082,779, leading its independent auditors to express substantial doubt about its ability to continue as a going concern.
• The company intends to spend approximately $1.5 million over the next 18 months on software and hardware development, regulatory approvals, and intellectual property protection for the ZSmile Platform.
• The global clear aligners market was estimated at $6.29 billion in 2022 and is projected to reach $46.3 billion by 2030, with a compound annual growth rate (CAGR) of 28.34%.
• Dror Ortho-Design aims to address a total addressable market of 22 million people by 2028, focusing on malocclusions related to the 'social six' teeth, and plans to leverage teledentistry and direct-to-consumer sales.
• The company is offering an unspecified number of common stock shares, prefunded warrants, and underwriter warrants, with an assumed public offering price of $[] per share, and plans to apply for listing on the NYSE American.
• A 1-for-[] reverse stock split is expected to be effected prior to or upon the effectiveness of the registration statement.
• Net proceeds from the offering are estimated to be approximately $[] million, or $[] million if the over-allotment option is fully exercised, primarily for working capital and general corporate purposes.

Sentiment

Score: 3

Explanation: The company presents an innovative product with significant market potential and patented technology. However, its current financial state is very weak, marked by recurring losses, negative cash flow, and a 'going concern' warning from auditors. The success of the offering and future operations are highly dependent on obtaining regulatory approvals and market acceptance, which are uncertain. The overall sentiment is cautious due to high risks despite the promising technology.

Positives

• Dror Ortho-Design has developed a proprietary AI-based orthodontic platform (ZSmile) with patented technology, offering a discreet and less painful alternative to existing aligner solutions.
• The company's predecessor first-generation Aerodentis System received FDA 510(k) clearance in April 2020, demonstrating prior regulatory success.
• The global clear aligners market is projected for significant growth, from $6.29 billion in 2022 to $46.3 billion by 2030 (28.34% CAGR), indicating a large market opportunity.
• The ZSmile Platform is designed to be used by both orthodontists and general dentists, expanding the target distribution channel, and potentially facilitating direct-to-consumer sales in the future.
• The company's technology includes AI-based image analysis that aims to eventually replace the need for intraoral scans for certain cases, potentially increasing efficiency and reducing treatment delivery cycles.
• The ZSmile Smart Aligner System features a redesigned micropump and motor for increased pressure capacity, efficiency, and durability, and is IoT-enabled for secure communication.
• The company plans to utilize cost-effective 3D printing for its single smart aligner, a superior method for precision and customizability not widely adopted by traditional aligner platforms due to multi-aligner requirements.
• The company has a research and development team with strong backgrounds in AI, data science, medical device development, and computer vision, including members from elite Israeli intelligence units.
• The company has three issued U.S. patents and four pending U.S. patents, covering critical aspects of its technology, with expirations extending to 2040.

Negatives

• The company is in the development stage, has no current revenues, and has incurred significant recurring net operating losses, with an accumulated deficit of $20.08 million as of March 31, 2025.
• Independent auditors have expressed substantial doubt about the company's ability to continue as a going concern due to insufficient liquidity and recurring losses.
• The new ZSmile Platform has not yet filed for or received the necessary FDA 510(k) clearance, which is required prior to marketing in the U.S., posing a significant regulatory hurdle.
• The company faces intense competition from large, internationally established aligner companies like Align Technologies, Dentsply Sirona, 3M Clarity Aligners, and Straumann Group, which have greater resources and established channels.
• Future profitability is uncertain and depends on widespread market acceptance of the Platform by dental professionals and consumers, which is not assured.
• The company's business model relies on the continued and widespread acceptance of teledentistry, which represents a change from traditional orthodontic treatment and may face consumer reluctance.
• There is no established trading market for the Prefunded Warrants, and the company does not intend to list them, limiting their liquidity.
• The company's common stock is currently traded on the OTC Pink Market, which will become the OTCID Basic Market, and there is no assurance that its application to list on the NYSE American will be approved, potentially leading to less liquid trading.
• The company has identified a material weakness in its internal control over financial reporting due to limited personnel and the absence of a Chief Financial Officer overseeing day-to-day operations and financial reporting.

Risks

• The company's financial statements have been prepared on a going concern basis, and it must raise additional capital to fund operations to continue as a going concern.
• Operations are conducted in Israel, exposing the company to economic, political, geopolitical, and military conditions in the region, including the ongoing conflict with Hamas and Hezbollah, which could disrupt business, supply chains, and fundraising.
• Global and regional economic conditions, including inflation, currency exchange rate fluctuations, and recessions, could materially affect business, results of operations, and financial condition by impacting consumer confidence and demand for elective treatments.
• The company is in the development stage, is not generating revenues, and has no operating history as a manufacturer and distributor of orthodontic medical devices or platforms for consumer use, making future projections uncertain.
• There is no assurance that the ZSmile Platform will achieve wide acceptance by intended consumers or the market generally, which could harm future financial performance.
• The company expects continued operating losses and cannot be certain of future profitability, with significant expenditures anticipated for development and marketing.
• Net revenues will depend primarily on the ZSmile Platform, and any decline in sales or average selling price could adversely affect net revenues, gross margin, and net income.
• The company will face competition from large internationally established aligner companies whose products have been widely accepted, and may be unable to compete effectively.
• Growth and future success depend on the ability to enhance the Platform or to develop, obtain regulatory clearance for, successfully introduce, and achieve market acceptance of new products and services.
• The company is subject to operating risks, including excess or constrained capacity and operational inefficiencies, which could adversely affect results of operations.
• Issues with product development or enhancements, IT system integration, implementation, updates, and upgrades could disrupt operations and have a material impact on business and operating results.
• Complying with regulations enforced by the U.S. Food and Drug Administration (FDA) and other regulatory authorities is expensive and time-consuming, and failure to comply could result in substantial penalties.
• The company may not receive the necessary authorizations to market its Platform or any future new products, and any failure to timely do so may adversely affect its ability to grow its business.
• Certain modifications to products may require new 510(k) clearance or other marketing authorizations, which could delay market introduction.
• Ongoing changes in healthcare regulation could negatively affect revenues, business, and financial condition.
• The company is subject to federal, state, and foreign fraud and abuse laws, health information privacy and security laws (e.g., HIPAA, GDPR, CCPA), and transparency laws, which, if violated, could subject it to substantial penalties and adverse publicity.
• Success depends in part on proprietary technology, and inability to successfully enforce intellectual property rights could harm competitive position, while potential infringement of others' IP could severely limit business growth.
• The relative lack of U.S. public company experience of the management team may put the company at a competitive disadvantage regarding U.S. securities laws and GAAP compliance.
• The common stock is not currently listed on any major stock exchange and there is a limited market for shares, leading to potential wide fluctuations and reduced liquidity.
• The company is subject to penny stock rules, which will make shares more difficult to sell and may reduce trading activity.
• Future sales of significant amounts of common stock, including from the expiration of lock-up provisions, may depress the stock price.
• Changes in, or interpretations of, accounting rules and regulations could result in unfavorable accounting charges.
• The identified material weakness in internal control over financial reporting (limited personnel, no CFO oversight) could adversely affect financial reporting accuracy and timing, and compliance.
• The effective tax rate may vary significantly due to global economic changes, legal entity structure, tax laws, and audit outcomes.
• The business will be exposed to potential liability for product quality and safety, advertising, and sales practices, which could result in substantial expenses or damages.

Future Outlook

Dror Ortho-Design, Inc. anticipates continued significant operating losses as it develops its ZSmile Platform and does not expect to generate revenue until development and testing are complete. The company intends to spend approximately $1.5 million over the next 18 months on software and hardware development, regulatory approvals, and IP protection. It plans to apply for NYSE American listing for its common stock, which is a condition for proceeding with the current offering. The company believes its AI-based image analysis of smartphone videos will eventually approach the accuracy of intraoral scans, potentially replacing them and dramatically increasing efficiency in the dental industry. Future success depends on market acceptance of its teledentistry model and ability to compete with established aligner companies.

Management Comments

• "We have reimagined the way people can correct their smile. We plan to disrupt the aligner market by offering millions of people a revolutionary alternative."
• "We believe that people do not need to change their lifestyle to correct their smile as they are required to do with existing aligner solutions."
• "We believe that recent rapid advancements in technology have made traditional aligner solutions no longer the most effective treatment option for smile correction."
• "The Company currently does not generate revenues to fund operations and anticipates that it will continue to incur significant losses as it continues to develop the Platform."
• "The Company intends to spend approximately $1.5 million over the next 18 months on software and hardware development as well as the accompanying regulatory approvals and IP protection associated with such software and hardware projects."
• "Management has substantial doubt about the Company’s ability to continue as a going concern."
• "Management does not believe that inflation has had a material impact on our business, sales, or operating results during the periods presented."
• "Our marketing strategy themes and promotional messages will emphasize the ease and convenience offered by our Platform as compared to other available treatments."
• "We believe that our Platform will compare favorably with respect to each of these factors [price, access, aesthetic appeal, comfort, duration, ease of use, orthodontist chair time]."

Industry Context

Dror Ortho-Design operates within the rapidly transforming dental industry, specifically targeting the clear aligners market, which is projected for substantial growth from $6.29 billion in 2022 to $46.3 billion by 2030. The company aims to disrupt this market by offering a unique AI-based, nighttime-use solution (ZSmile) that contrasts with traditional all-day plastic aligners. This positions Dror Ortho-Design against major established players like Align Technologies (Invisalign), Dentsply Sirona (Byte), 3M Clarity Aligners, and Straumann Group. The company also seeks to capitalize on the growing trend of general dentists performing orthodontic procedures and the increasing acceptance of teledentistry, which could expand its distribution channels beyond traditional orthodontist-centric models.

Comparison to Industry Standards

• Dror Ortho-Design's ZSmile Platform aims to differentiate from competitors like Align Technologies (Invisalign) by using a single smart aligner with pulsating air for nighttime use, contrasting with the 12-15 month process of wearing multiple plastic aligners all day.
• The company claims its method is 'less painful' and 'discreet' compared to existing solutions, which often cause pain with new aligners and restrict blood circulation.
• While traditional aligner therapies (e.g., Invisalign) require multiple in-office visits, Dror Ortho-Design's teledentistry model aims for 'minimal need for office visits' and remote monitoring, aligning with a broader industry trend towards remote healthcare.
• The company's first-generation Aerodentis System received FDA 510(k) clearance, similar to regulatory pathways for other Class II medical devices in the orthodontic space, but the new ZSmile Platform requires a new clearance.
• Dror Ortho-Design's plan to use 3D printing for actual aligners, rather than just models, is presented as a 'significant development' and 'superior method for production due to its level of precision and customizability,' which is not financially viable for traditional multi-aligner systems.
• The company's focus on 'social six' malocclusions (front upper and lower six teeth) targets a specific segment of the market, potentially allowing for a more focused approach compared to broader orthodontic solutions offered by competitors.

Management Changes

Corporate Governance

Legal Proceedings

• The company may be subject to routine litigation incidental to its business from time to time, but management believes there are no matters that would have a material adverse effect on results of operations and financial condition.

Related Party Transactions

• On July 5, 2023, the company entered into a Share Exchange Agreement with Private Dror and its shareholders, including Moshe Shvets (CTO and director) and AIGH (a >5% beneficial owner), resulting in the exchange of Private Dror shares for Dror Ortho-Design common and Series A Preferred Stock.
• In connection with the Share Exchange, a Private Placement occurred on August 14, 2023, and September 13, 2023, where Eliyahu Haddad (CEO and director), Moshe Shvets, and AIGH purchased common stock, Series A Preferred Stock, and warrants, providing aggregate gross proceeds of $5,225,000.
• The company entered into indemnification agreements with its directors and executive officers.
• Yehuda Englander (director) has a consulting agreement (amended February 7, 2024) for financial and strategic consulting services, receiving a monthly cash fee of $2,500 and options to purchase 9,597,675 shares of common stock.
• Chaim Ravad (director) had a consulting agreement (entered February 7, 2024) for board services, receiving a cash fee of $5,000 per month, which terminated upon reaching an aggregate payment of $55,000.
• Oriole Avenue Inc., an entity owned by Yaacov Bodner (a >5% stockholder), entered into a consulting agreement on August 8, 2023, for shareholder and investor relations services, receiving $145,000 in cash payments and warrants to purchase 10,454,500 shares of common stock.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the current public offering and future capital raises. Existing shareholders may also face reduced liquidity due to the stock trading on the OTC Pink Market and uncertainty regarding NYSE American listing. The 'going concern' warning poses a substantial risk to investment value.
• **Employees**: The company's ability to continue as a going concern directly impacts job security. The identified material weakness in internal controls due to limited personnel suggests potential strain on existing employees. Military call-ups in Israel could affect employee availability.
• **Customers (Future)**: The success of the ZSmile Platform depends on its acceptance by dental professionals and consumers. Delays in FDA clearance could postpone product availability. The teledentistry model aims to provide convenience and less painful treatment, potentially benefiting patients.
• **Suppliers/Vendors**: The company's reliance on outsourced third-party vendors for R&D and manufacturing means their operations could be impacted by the company's financial stability and geopolitical conditions in Israel.
• **Creditors**: The 'going concern' warning and recurring losses indicate increased risk for current and future creditors, including those who provided recent bridge loans.

Next Steps

• Effect a 1-for-[] reverse stock split prior to or upon effectiveness of the registration statement.
• Apply to have common stock listed for trading on the NYSE American, which is a condition for proceeding with this offering.
• File a 510(k) submission for the ZSmile Platform to obtain FDA clearance for marketing in the U.S.
• Continue software and hardware development for the ZSmile Platform, including UI/UX and system integration.
• Develop and introduce new products and services to maintain or increase sales.
• Attract and retain relationships with key orthodontists, dentists, and dental organizations to educate the consumer market on the Platform.
• Implement and improve operational, financial, and management information systems to manage current and anticipated future operations effectively.
• Remediate the identified material weakness in internal control over financial reporting by increasing personnel and establishing proper oversight for accounting and financial reporting functions.
• Finalize interest and repayment terms for the $300,000 bridge loans received from existing investors.

Key Dates

Recommendation

Keywords

Orthodontics, Clear Aligners, Teledentistry, AI-based medical device, Dental technology, Smile correction, Medical device development, FDA clearance, S-1 filing, Public offering, Biotech, Healthcare technology, Israel operations